Previous close | 0.7810 |
Open | 0.7610 |
Bid | 0.7264 x 100 |
Ask | 0.7776 x 100 |
Day's range | 0.7400 - 0.7992 |
52-week range | 0.7400 - 1.7600 |
Volume | |
Avg. volume | 771,359 |
Market cap | 31.537M |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.7400 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.83 |
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company d
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company
Just because a business does not make any money, does not mean that the stock will go down. For example, although...